In the Original Investigation titled "Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial,"1 published online May 29, 2018, there was an error in Figure 1. In the bottom middle box, reflecting the number of patients who completed double-blind treatment in the galcanezumab 240-mg dose group, the percentage should read 82.5%. This article was corrected online.
ASJC Scopus subject areas
- Clinical Neurology